Phaseline

Companies › COUR Pharmaceutical Development Company

COUR Pharmaceutical Development Company: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CNP-103–Phase 1Type 1 Diabetes MellitusDec 2026
CNP-106
Antigenic AChR peptide pool (AChRα and AChRε peptides) delivered in PLGA polymer particles
CHRNA1, CHRNEPhase 1Myasthenia Gravis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06106672CNP-106Phase 1Myasthenia GravisNeurologyJun 2026
NCT06783309CNP-103Phase 1Type 1 Diabetes MellitusMetabolic and endocrineDec 2026

From the company's SEC filings

Complete response letters from FDA

Targets

CHRNA1 (1) CHRNE (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.